Patent application number | Description | Published |
20090172192 | Mapless Global Traffic Load Balancing Via Anycast - Techniques are described for directing connections between clients and the closest web server. Authoritative DNS resolvers of a network are placed at edges of the network. Using anycast, the authoritative DNS resolvers advertise routes of their destination netblock to the Internet. A request from a client to connect to the network is routed, based upon BGP tables, to the closest particular authoritative DNS resolver. Once the request is received, a response is sent to the client with the IP address of the closest web server. The closest web server is determined through in-network health check measurements, with the authoritative DNS resolvers dynamically selecting IP addresses closest to themselves. Routing protocols that directed the packet to the closest authoritative DNS resolver also dictate the route of subsequent traffic to the network. Thus, the closest web server selected by the authoritative DNS resolver is also the closest web server to the client. | 07-02-2009 |
20100235441 | MAPLESS GLOBAL TRAFFIC LOAD BALANCING VIA ANYCAST - Techniques are described for directing connections between clients and the closest web server. Authoritative DNS resolvers of a network are placed at edges of the network. Using anycast, the authoritative DNS resolvers advertise routes of their destination netblock to the Internet. A request from a client to connect to the network is routed, based upon BGP tables, to the closest particular authoritative DNS resolver. Once the request is received, a response is sent to the client with the IP address of the closest web server. The closest web server is determined through in-network health check measurements, with the authoritative DNS resolvers dynamically selecting IP addresses closest to themselves. Routing protocols that directed the packet to the closest authoritative DNS resolver also dictate the route of subsequent traffic to the network. Thus, the closest web server selected by the authoritative DNS resolver is also the closest web server to the client. | 09-16-2010 |
Patent application number | Description | Published |
20100022547 | Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections - One aspect of the present invention relates to compounds, and pharmaceutically acceptable salts and prodrugs thereof, that are useful as inhibitors of IMPDH. The invention also provides pharmaceutical compositions comprising the compounds of the invention which selectively inhibit parasitic IMPDH. In certain embodiments, the present invention relates to selective inhibition of | 01-28-2010 |
20120101096 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections - Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound of the invention selectively inhibits a parasitic IMPDH versus a host IMPDH. Further, the invention provides pharmaceutical compositions comprising one or more compounds of the invention. The invention also relates to methods of treating various parasitic and bacterial infections in mammals. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants. | 04-26-2012 |
20120264760 | Compounds and Methods for Treating Mammalian Gastrointestinal Parasitic Infections - One aspect of the present invention relates to compounds, and pharmaceutically acceptable salts and prodrugs thereof, that are useful as inhibitors of IMPDH. The invention also provides pharmaceutical compositions comprising the compounds of the invention which selectively inhibit parasitic IMPDH. In certain embodiments, the present invention relates to selective inhibition of | 10-18-2012 |
20130116417 | Methods for the Development of Vaccines Based on Oligosaccharide-Oligonucleotide Conjugates - Described herein are oligosaccharide-oligonucleotide conjugates useful as vaccines against one or more human or veterinary therapeutic indications, and methods of synthesizing and identifying them. The conjugates may be identified using non-human antibodies as binding targets, thereby expanding the power and scope of the invention. Efficacious conjugates may be identified through an iterative. | 05-09-2013 |
20130190340 | Small-Molecule-Targeted Protein Degradation - Certain aspects of the invention relate to compounds, compositions and methods that are useful for treating or preventing a disease in a subject by enhancing the degradation of a protein. In other aspects, said compounds can be useful research tools for investigating protein degradation. In other aspects, said compounds are useful research tools for investigating protein function. In certain embodiments, the degraded protein is implicated in a disease or disorder whose pathology is related at least in part to the excessive expression of the protein or the expression of a mutant form of the protein. | 07-25-2013 |
20150099781 | Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections - Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound of the invention selectively inhibits a parasitic IMPDH versus a host IMPDH. Further, the invention provides pharmaceutical compositions comprising one or more compounds of the invention. The invention also relates to methods of treating various parasitic and bacterial infections in mammals. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants. | 04-09-2015 |
Patent application number | Description | Published |
20080214990 | Fluid Conduit Connection - A fluid conduit connector assembly includes a connector having a body with an inner surface defining a fluid channel. The connector also includes an inlet region for flow of fluid into the fluid channel, and an outlet region for flow of fluid from the fluid channel. The connector further includes an axial alignment member outward of the body, and a pair of flexible tabs arranged generally circumferentially of the alignment member and outward of the body. The connector can be configured as a day-side connector, transfer member with check valve, and/or patient-side connector. An implementation includes a day-side connector, a patient-side connector, and a transfer member, each of which has a pair of flexible tabs. The pairs of tabs are configured such that the transfer member releasably couples the day-side and patient-side connectors. A method for aseptically connecting a fluid conduit is also disclosed. | 09-04-2008 |
20100152647 | Cartridge Assembly - The present disclosure relates to a cartridge assembly. The cartridge assembly includes an inflow cartridge and an outflow cartridge removably coupled to the inflow cartridge. An outflow cartridge and a surgical fluid management system are also disclosed. | 06-17-2010 |
20110196314 | FLUID CONDUIT CONNECTION - A fluid conduit connector assembly includes a connector having a body with an inner surface defining a fluid channel. The connector also includes an inlet region for flow of fluid into the fluid channel, and an outlet region for flow of fluid from the fluid channel. The connector further includes an axial alignment member outward of the body, and a pair of flexible tabs arranged generally circumferentially of the alignment member and outward of the body. The connector can be configured as a day-side connector, transfer member with check valve, and/or patient-side connector. An implementation includes a day-side connector, a patient-side connector, and a transfer member, each of which has a pair of flexible tabs. The pairs of tabs are configured such that the transfer member releasably couples the day-side and patient-side connectors. A method for aseptically connecting a fluid conduit is also disclosed. | 08-11-2011 |
20110301623 | TISSUE RESECTING SYSTEM - A surgical system includes a first instrument defining a first channel and a second instrument receivable by the first channel. The second instrument defines a second channel. A valve coupled to the first instrument controls fluid flow through the first channel, such that impedance of fluid flow through the first channel is substantially the same without the second instrument received in the first channel and with the first channel partially blocked by the second instrument. In another aspect, a surgical apparatus includes an outer member and an inner member received within the outer member to define a first channel therebetween. The inner member houses an optical lens and defines a second channel for receiving a surgical instrument. The first and second channels are configured such that a pump having an inflow rate of up to about 0.7 L/min connected to the second channel can maintain fluid pressure inside an organ. | 12-08-2011 |
20120330240 | SURGICAL FLUID MANAGEMENT - A fluid flow device includes a housing configured to releasably mate with a surgical control unit for controlling fluid flow during a surgical procedure. First and second ports measure fluid pressure within a fluid path provided within the housing. The fluid flow device includes a restrictor for restricting fluid flow at a restriction location along the fluid path. The first port is located upstream of the restriction location and the second port is located downstream of the restriction location. A fluid pump is provided within the housing. | 12-27-2012 |
20130225928 | TISSUE RESECTING SYSTEM - A surgical system includes a first instrument defining a first channel and a second instrument receivable by the first channel. The second instrument defines a second channel. A valve coupled to the first instrument controls fluid flow through the first channel, such that impedance of fluid flow through the first channel is substantially the same without the second instrument received in the first channel and with the first channel partially blocked by the second instrument. In another aspect, a surgical apparatus includes an outer member and an inner member received within the outer member to define a first channel therebetween. The inner member houses an optical lens and defines a second channel for receiving a surgical instrument. The first and second channels are configured such that a pump having an inflow rate of up to about 0.7 L/min connected to the second channel can maintain fluid pressure inside an organ. | 08-29-2013 |
20140371708 | TISSUE RESECTING SYSTEM - A surgical system includes a first instrument defining a first channel and a second instrument receivable by the first channel. The second instrument defines a second channel. A valve coupled to the first instrument controls fluid flow through the first channel, such that impedance of fluid flow through the first channel is substantially the same without the second instrument received in the first channel and with the first channel partially blocked by the second instrument. In another aspect, a surgical apparatus includes an outer member and an inner member received within the outer member to define a first channel therebetween. The inner member houses an optical lens and defines a second channel for receiving a surgical instrument. The first and second channels are configured such that a pump having an inflow rate of up to about 0.7 L/min connected to the second channel can maintain fluid pressure inside an organ. | 12-18-2014 |